We are a biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.
We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.
We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.
Nov 26, 2020 9:25 AM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News and Events
NGM to Host Virtual R&D Day on December 9, 2020Read more
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 VirtualRead more
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial ResultsRead more